GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Abaloparatide

Company
University of Wisconsin, Madison
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Abaloparatide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06164795

    Sequential Therapies After Osteoanabolic Treatment

    424 General Military Hospital 150 participants Est. completion 2027-12 8 sites
    Other conditions: Osteoporosis, Postmenopausal
    View official trial listing →
  • Recruiting NCT NCT07616401

    MicroRNA and Markers and Therapeutic Response to Romosozumab and Abaloparatide in Postmenopausal Osteoporosis

    Not yet reported Istituto Auxologico Italiano 42 participants Est. completion 2029-08-31 2 sites Stand-alone
    Other conditions: Osteoporosis, Menopause
    View official trial listing →
  • Completed NCT NCT00542425

    Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

    Not yet reported Radius Health, Inc. 222 participants Est. completion 2009-06 1 site
    Other conditions: Osteoporosis
    View official trial listing →
  • Completed NCT NCT01343004

    Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

    Not yet reported Radius Health, Inc. 2463 participants Est. completion 2014-10 28 sites Stand-alone
    Other conditions: Osteoporosis, Postmenopausal Osteoporosis
    View official trial listing →
  • Completed NCT NCT01657162

    Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

    Not yet reported Radius Health, Inc. 1139 participants Est. completion 2016-10-03 25 sites Stand-alone
    Other conditions: Postmenopausal Osteoporosis
    View official trial listing →
  • Completed NCT NCT01674621

    Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

    Not yet reported Radius Health, Inc. 250 participants Est. completion 2013-08-02 9 sites Stand-alone
    Other conditions: Post Menopausal Osteoporosis
    View official trial listing →
  • Completed NCT NCT03512262

    Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

    Not yet reported Radius Health, Inc. 228 participants Est. completion 2021-09-08 34 sites Stand-alone
    Other conditions: Osteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis, Osteoporosis Senile, Osteoporosis of Vertebrae
    View official trial listing →
  • Withdrawn NCT NCT03708926

    Effect of Abaloparatide on Lumbar Disc Degeneration

    Not yet reported Johns Hopkins University Est. completion 2024-02 1 site Stand-alone
    Other conditions: Degeneration Disc Intervertebral
    View official trial listing →
  • Completed NCT NCT03710889

    Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

    Not yet reported Radius Health, Inc. 23 participants Est. completion 2020-07-15 4 sites Stand-alone
    Other conditions: Osteoporosis, Postmenopausal, Osteoporosis, Osteoporosis Vertebral, Osteoporosis Risk, Osteoporosis Fracture, Osteoporosis Localized to Spine, Osteoporosis, Age-Related, Osteoporosis Senile, Osteoporosis of Vertebrae
    View official trial listing →
  • Completed NCT NCT03746041

    A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes

    Not yet reported University of Rochester 20 participants Est. completion 2022-06-06 1 site Stand-alone
    Other conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03841058

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

    Not yet reported Hospital for Special Surgery, New York 96 participants Est. completion 2027-02 1 site Stand-alone
    Other conditions: Spinal Fusion
    View official trial listing →
  • Completed NCT NCT04064411

    Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

    Not yet reported Radius Health, Inc. 511 participants Est. completion 2021-11-09 97 sites Stand-alone
    Other conditions: Postmenopausal Osteoporosis
    View official trial listing →
  • Completed NCT NCT04167163

    Abaloparatide Before Total Knee Arthroplasty

    Not yet reported University of Wisconsin, Madison 58 participants Est. completion 2025-04-03 1 site
    Other conditions: Osteoporosis, Arthroplasties, Knee Replacement
    View official trial listing →
  • Completed NCT NCT04249232

    Abaloparatide and Pelvic Fracture Healing

    Not yet reported Hospital for Special Surgery, New York 48 participants Est. completion 2024-04-25 3 sites
    Other conditions: Fracture of Pelvis (Disorder)
    View official trial listing →
  • Completed NCT NCT04366726

    Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)

    Not yet reported Radius Health, Inc. 22 participants Est. completion 2019-05-14 1 site Stand-alone
    Other conditions: Postmenopausal Osteoporosis
    View official trial listing →
  • Active, not recruiting NCT NCT04467983

    Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

    Not yet reported Hospital for Special Surgery, New York 70 participants Est. completion 2026-12-01 1 site
    Other conditions: Osteoporosis, Postmenopausal
    View official trial listing →
  • Withdrawn NCT NCT04626141

    Supracondylar Distal Femur Fractures and Abaloparatide

    Not yet reported Daniel Horwitz Est. completion 2025-06 1 site Stand-alone
    Other conditions: Femoral Fractures
    View official trial listing →
  • Completed NCT NCT04663464

    Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.

    Not yet reported Radius Health, Inc. 52 participants Est. completion 2021-11-19 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Terminated NCT NCT04760782

    PTH Analog Type II Odontoid Fracture

    Not yet reported David Lunardini 22 participants Est. completion 2023-08-14 1 site Stand-alone
    Other conditions: Odontoid Fracture
    View official trial listing →
  • Completed NCT NCT04936984

    Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.

    Not yet reported Radius Health, Inc. 36 participants Est. completion 2021-08-13 1 site Stand-alone
    Other conditions: Osteoporosis
    View official trial listing →
  • Completed NCT NCT04974723

    Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

    Radius Health, Inc. 22054 participants Est. completion 2021-09-30 1 site
    Other conditions: Osteoporosis, Postmenopausal
    View official trial listing →
  • Status unknown NCT NCT06154187

    Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis

    Not yet reported Pharmbio Korea Co., Ltd. 60 participants Est. completion 2025-11 1 site Stand-alone
    Other conditions: Osteoporosis
    View official trial listing →
  • Not yet recruiting NCT NCT06753864

    A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects

    Not yet reported The Affiliated Hospital of Qingdao University 32 participants Est. completion 2025-05-01 1 site Stand-alone
    Other conditions: Osteoporosis
    View official trial listing →
  • Not yet recruiting NCT NCT06898060

    To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

    Not yet reported Qilu Pharmaceutical Co., Ltd. 282 participants Est. completion 2027-05
    Other conditions: Postmenopausal Women With Osteoporosis
    View official trial listing →
  • Enrolling by invitation NCT NCT07587775

    The Effect of Osteoporotic Medications on Vertebral Bone Quality Score

    Not yet reported State University of New York at Buffalo 60 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Lumbar Degenerative Disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.